Will Gillanders

Medicine & Life Sciences

1. Breast Neoplasms 100%
2. T-Lymphocytes 39%
3. Mammaglobin A 37%
4. Neoplasms 37%
5. Epithelial Cell Adhesion Molecule 31%
6. Cancer Vaccines 25%
7. Vaccination 24%
8. Peptides 24%
9. Antigens 19%
10. Breast 18%
11. Lymph Nodes 18%
12. Segmental Mastectomy 17%
13. Vaccines 17%
14. Pancreatic Neoplasms 16%
15. Recurrence 16%
16. DNA Vaccines 15%
17. Immunity 15%
18. Sentinel Lymph Node Biopsy 15%
19. Adenocarcinoma 15%
20. Sentinel Lymph Node 14%
21. Brachytherapy 13%
22. Carcinoma, Intraductal, Noninfiltrating 12%
23. Dendritic Cells 12%
24. Triple Negative Breast Neoplasms 11%
25. Neoplasm Metastasis 10%
26. Neoplasm Micrometastasis 10%
27. Therapeutics 10%
28. Mastectomy 10%
29. Survival 9%
30. T-Lymphocyte Epitopes 8%
31. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 8%
32. CD8 Antigens 8%
33. Drug Therapy 8%
34. Thyroidectomy 7%
35. Reverse Transcription 7%
36. Neoadjuvant Therapy 7%
37. Epitopes 7%
38. Genes 7%
39. Ligands 7%
40. Cytokines 7%
41. Technology 7%
42. Clinical Trials 7%
43. Immunotherapy 6%
44. Antigen Presentation 6%
45. HLA-A2 Antigen 6%
46. Cohort Studies 6%
47. Myeloid-Derived Suppressor Cells 6%
48. Fine Needle Biopsy 6%
49. Poly I-C 6%
50. poly-N-acetyl glucosamine 6%